Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.24 and traded as high as $1.64. Cortexyme shares last traded at $1.64, with a volume of 27,429 shares changing hands.
Cortexyme Stock Performance
The firm’s 50 day moving average is $1.86 and its 200-day moving average is $1.24. The firm has a market cap of $49.45 million, a price-to-earnings ratio of -0.55 and a beta of 1.40.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Articles
- Five stocks we like better than Cortexyme
- Consumer Staples Stocks, Explained
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- How to Invest in Small Cap Stocks
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Stock Average Calculator
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
